All News

RheumNow Podcast square

The Window of Opportunity (5.24.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?

Read Article
podcast logo

"Don't You Know Who I am?" (5.17.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?

Read Article
RheumNow Podcast square

Immunosuppression Increasing (2.23.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on RheumNow.com; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients.

Read Article
infusion.biologic.jpg

CD19 CAR T-Cell Therapy in Autoimmune Disease

Jack Cush, MD

The NEJM has published the results of CD19 B cell depletion (by CAR-T cell therapy) in autoimmune disease patients, demonstrating it to be feasible, safe, and efficacious.

Read Article
RheumNow Podcast square

VITAL Info on Autoimmune Disease (2.9.2024)

Jack Cush, MD

Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".

Read Article
PSS.scleroderma.arthritis.contractures

Inflammatory Arthritis in Systemic Sclerosis is Problematic

Jack Cush, MD

Inflammatory arthritis (IA) is a common manifestation in systemic sclerosis (SSc), affecting nearly one-third of patients.

Read Article
Dead Words Eulogy Cover Image

Dead Words Eulogy

Jack Cush, MD

The trouble with rheumatology may be the words we live by. Welcome to the eulogy for rheumatology 'dead words'. We're here today to celebrate the loss of rheumatology past. These are dead words in rheumatology, words fortified unfortunately by history and habit. The lexicon of rheumatology is unique, it's challenging and it's mostly incomprehensible to those who don't know...but those are the cornerstones of the greatest of medical subspecialties. 

Read Article
RheumNow Podcast square

CBT or Naltrexone in Fibromyalgia (12.8.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  Be sure to catch the early registration break for 2024 RheumNow Live.

Read Article
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort https://t.co/IB0cOAFnwl https://t.co/zpwm3JRKU4

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Review article of Interstitial Lung Dz Assoc w/ Systemic Sclerosis. SSc-ILD prevalence ranges 25-95%; ILD is a main cause of morbidity and mortality, contributing to 35% of deaths https://t.co/8mMFbDu4gi https://t.co/nQ4GfNcMWt

Links:

Dr. John Cush RheumNow ( View Tweet)
Who is confused about what to do for #GI symptoms in #scleroderma? @TimKanieckiMD does a masterful breakdown of gut involvement for @jhrheumatology rounds. You can read further in: https://t.co/xw6EElGIWl @ZsuzsannaM55365 would be proud! #MentoredResearchProjects #dysmotility https://t.co/yLVD7Vo1SJ

Links:

Johns Hopkins Rheumatology Fellows JHRheumFellows ( View Tweet)
IL-1 recept accessory protein (IL1RAP) shown to block mediators (IL-1, IL33, IL36) that may drive systemic sclerosis. In vitro, IL1RAP inhibited fibroblasts and endothelial cells; in mouse models of SSc anti-IL1RAP decr dermal & pulmonary fibrosis. https://t.co/6YE02P4rjR https://t.co/mzw7t88Jzl

Links:

Dr. John Cush RheumNow ( View Tweet)
Epigenetics and Autoimmune Skin Disease The central dogma proposed that genetic information predominantly transfers from DNA to RNA during gene expression to make a functional product protein. https://t.co/VgQE2yYYmq https://t.co/fAWBifCyWv

Links:

Dr. John Cush RheumNow ( View Tweet)
Cabaletta Bio announced FDA has granted Orphan Drug Designation to CABA-201, a 4-1BB-containing human CD19-CAR T cell agent, to treat systemic sclerosis. RESET (REstoring SElf-Tolerance) trial program includes the Phase 1/2 RESET-SSc trial https://t.co/Vo5jIHBrPj https://t.co/TXvFypbZdw

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA grants orphan drug designation to CAR T-cell therapy for systemic sclerosis https://t.co/KZKSy2sbNk https://t.co/5abz8MeYGK

Links:

Dr. John Cush RheumNow ( View Tweet)
Review of autoimmune Dz & adverse preg outcomes: Incr risk of: - Miscarriage w/ Sjögrens (RR 8.85) & SLE (OR 4.9) - Preeclampsia w/ SLE (OR 3.2) - IUGR w/ scleroderma (OR 3.2) & celiac (OR 1.71) - Preterm birth w/ SLE (OR 2.79). https://t.co/bll2x2aS9Z https://t.co/Eg0sVBcPmR

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 43 SSc patients w/ gangrene shows Smoking Hx ; positive-ACA, ANCA, APL Abs & high ESR were independent risk factors for digital gangrenes in SSc. Vasculitis and macrovascular disease may contribute to the progression of digital gangrene https://t.co/3DY2Hx19s0 https://t.co/BfXANmckwF

Links:

Dr. John Cush RheumNow ( View Tweet)
Marketing analysis of systemic sclerosis prevalence estimates, from 7 major countries, ~150,000 SSc pts in 2022 (47% from US; 20% Japan; 10% UK). https://t.co/0zJFdq05Xd https://t.co/HWM3LNtHbS

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read overview of SJOGRENS SYNDROME, which can be Primary SS or Secondary (15% in SLE, 20% RA, & 30% systemic sclerosis). SS Organ involvement: - CNS 2-17% - Renal <=10% - ILD 10-20% -MSK 45-56% https://t.co/RElOFfP2xr https://t.co/aJI041VCuE

Links:

Dr. John Cush RheumNow ( View Tweet)
NVC in 1356 #SSc registry pts classified as early, active or‘late. Late pattern seen in 40%: signific. assoc w/ dcSSc (OR=1.96), ILD (OR=1.29), renal crisis (OR=3.46), digital ulcer (OR=1.29), &amp; topoisomerase I Abs (OR=1.39) https://t.co/RgET0HbImf https://t.co/Ex3nKto6JW

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×